Motivated by the recent implication of
cysteine protease cathepsin L as a potential target for anti-
cancer drug development, we used a conditional MycERTAM;Bcl-xL model of pancreatic neuroendocrine
tumorigenesis (
PNET) to assess the role of
cathepsin L in Myc-induced
tumor progression. By employing a
cysteine cathepsin activity probe in vivo and in vitro, we first established that
cathepsin activity increases during the initial stages of MycERTAM;Bcl-xL
tumor development. Among the
cathepsin family members investigated, only
cathepsin L was predominately produced by beta-
tumor cells in neoplastic pancreata and, consistent with this,
cathepsin L mRNA expression was rapidly upregulated following Myc activation in the beta cell compartment. By contrast,
cathepsins B, S and C were highly enriched in
tumor-infiltrating leukocytes. Genetic deletion of
cathepsin L had no discernible effect on the initiation of neoplastic growth or concordant angiogenesis. However, the
tumors that developed in the
cathepsin L-deficient background were markedly reduced in size relative to their typical wild-type counterparts, indicative of a role for
cathepsin L in enabling expansive
tumor growth. Thus, genetic blockade of
cathepsin L activity is inferred to retard Myc-driven
tumor growth, encouraging the potential utility of pharmacological inhibitors of
cysteine cathepsins in treating late stage
tumors.